Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a ...

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...

In the United States, patients with renal cell carcinoma are more likely to die from COPD than the general population. Chronic obstructive pulmonary disease (COPD) is a major cause of death among ...

Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

Impact of initial local therapy (LT) in the combination treatment era for metastatic renal cell carcinoma (mRCC): Subgroup analysis from ProPaxi study. Mortality risk in clinical T1a renal cell ...

The following is a summary of “Risk factors for renal insufficiency and survival implications after radical nephrectomy and ...

Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University Hospital ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Metastatic renal cell carcinoma (mRCC) primary refractory patients to first-line IO-TKI and IO-IO combinations (Meet-URO 33 analysis). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...